Acute myeloid leukemia (AML) is the most common leukemia in adults and is still one of the most clinically challenging malignancies in the field of oncology.
For patients who have either refractory or relapsed disease, the best chance for long term cure is for patients who respond favorably to salvage therapy.
As the head of Sheba’s Leukemia Program, Dr. Jonathan Canaani’s research efforts focus on this unique patient segment with the aim of uncovering the specific molecular milieu associated with favorable response to salvage chemotherapy. Using next generation sequencing platforms, Dr. Canaani’s research will endeavor to utilize precision medicine approaches to guide rationale decision making for this high risk patient population.
Jonathan Canaani, MD
Sheba Medical Center